Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 333-350 , October 2000

Antisense therapy in cancer

References 

    REFERENCES
  1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and transformation by a specific oligonucleotide. Proc Natl Acad Sci USA. 1978;75:280–284
  2. Nakai D, Seita T, Terasaki T, Iwasa S, Shoji Y, Mizushima Y, et al. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. Pharmacol Exp Ther. 1996;278:1362–1372
  3. Rothenburg M, Johnson G, Laughlin C, Green I, Cradock J, Sarver N, et al. Oligonucleotides as antisense inhibitors of gene expression: therapeutic implications. J Natl Cancer Inst. 1989;81:1539–1544
  4. Warzocha K, Wotowiec D. Antisense strategy: Biological Utility and prospects in the treatment of hematological malignancies. Leukemia and Lymphoma. 1997;24:267–281
  5. Agrawal S. Factors affecting the specificity and mechanism of action of antisense oligonucleotide. Antisense Nucl Acids Drug Dev. 1999;9:371–375
  6. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proc Natl Acad Sci USA. 1998;95:195–200
  7. Kita K, Saito S, Morioka CY, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by antisense oligonucleotides specific to mutated K-ras genes. Int J Cancer. 1999;80:553–558
  8. Zhao Q, Temsamani J, Iadarola PL, Jiang ZW, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 1996;51:173–182
  9. Yi AK, Krieg AM. Rapid induction of mitogen-activated protein kinase by immune stimulatory CpG DNA. J Immunol. 1998;161:4493–4497
  10. Zhao Q, Temsamani J, Zhou R, Agrawal S. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucl Acids Drug Dev. 1997;7:495–502
  11. Moldoveanu Z, Love-Homan L, Huang WQ, Kreig AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 1998;16:1216–1224
  12. Krieg AM, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546–549
  13. Agrawal S, Iadarola PL, Temsamani J, Zhao Q, Shaw D. Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides. Bioorg Med Chem Lett. 1996;6:2219–2224
  14. Agrawal S, Zhao Q. Antisense therapeutics. Curr Opin Chem Biol. 1998;2:519–528
  15. Jansen B, Wadl H, Inoue SA, Trulzsch B, Selzer E, Duchene M, et al. Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res Dev. 1995;5:271–277
  16. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA. 1987;84:7706–7711
  17. Lesser DR, Grajkowski A, Kurpiewski MR, Koziol/kiewicz M, Stec WJ, Jen-Jacobson L. Stereoselective interaction with chiral phosphorothioates at the central DNA kink of the EcoRI endonuclease–GAATTC complex. J Biol Chem. 1992;267:24810–24818
  18. Stec WJ, Zon G, Uznanski B. Reversed-phase high-performance liquid chromatographic separation of diastereomeric phosphorothioate analogues of oligodeoxyribonucleotides and other backbone-modified congeners of DNA. J Chromatogr. 1985;326:263–280
  19. Meiss G, Friedhoff P, Hahn M, Gimadutdinow O, Pingoud A. Sequence preferences in cleavage of dsDNA and ssDNA by the extracellular Serratia marcescens endonuclease. Biochemistry. 1995;34:11979–11988
  20. Koziolkiewicz M, Wójcik M, Kobylanska A, Karwowski B, Rebowska A, Guga P, et al. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3′-exonuclease. Antisense Nucl Acids Drug Dev. 1997;7:43–48
  21. Stec WJ, Grajkowski A, Koziolkiewicz M, Uznanski B. Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates). Nucl Acids Res. 1991;19:5883–5888
  22. Stec WJ, Cierniewski CS, Okruszek A, Kobylanska A, Pawlowska Z, Koziolkiewicz M, et al. Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments. Antisense Nucleic Acid Drug Dev. 1997;7:567–573
  23. Koziolkiewicz M, Krakowiak A, Kwinkowski M, Boczkowska M, Stec WJ. Stereodifferentiation — the effect of P chirality of oligonucleoside phosphorothioates on the activity of bacterial RNase H. Nucl Acids Res. 1995;23:5000–5005
  24. Zhao Q, Song X, Waldschmidt T, Fisher E, Krieg AM. Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood. 1996;88:1788–1795
  25. Ma DD, Wei AQ. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk Res. 1996;20:925–930
  26. Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk Lymphoma. 1996;21:93–97
  27. Williams SA, Chang L, Buzby JS, Suen Y, Cairo MS. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt’s lymphoma cell growth. Leukemia. 1996;10:1980–1989
  28. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA. 1991;88:2351–2355
  29. Kronenwett R, Steidl U, Kirsch M, Sczakiel G, Haas R. Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood. 1998;91:852–862
  30. Yao GQ, Corrias S, Cheng YC. Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. Biochem Pharmacol. 1996;51:431–436
  31. Stein CA. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol. 1996;14:147–149
  32. Agrawal S, Iyer RP. Modified oligonucleotides as therapeutic and diagnostic agents. Curr Opin Biotechnol. 1995;6:12–19
  33. Gao WY, Han FS, Storm C, Egan W, Cheng YC. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and Rnase H: Implications for antisense technology. Mol Pharmacol. 1992;41:223–229
  34. Majumdar C, Stein CA, Cohen JS, Broder S, Wilson SH. Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry. 1989;28:1340–1346
  35. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem. 1995;270:2620–2627
  36. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA. 1997;94:979–984
  37. Bennett CF, Chiang MY, Wilson-Lingardo L, Wyatt J. Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides. Nucl Acids Res. 1994;22:3202–3209
  38. Dean NM, McKay R. Inhibition of protein kinase C α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA. 1994;91:11762–11766
  39. Maltese JY, Sharma H, Vassilev L, Narayanan R. Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides. Nucl Acids Res. 1995;23:1146–1151
  40. Khaled Z, Benimetskaya L, Khan T, Zetzer R, Sharma H, Narayanan R, et al. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucl Acids Res. 1996;24:737–745
  41. Stein CA, Cheng YC. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Science. 1993;261:1004–1012
  42. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 1996;14:376–387
  43. Bhan P, Bhan A, Hong M, Hartwell JG, Saunders JM, Hoke GD. 2′,5′-linked oligo-3′-deoxyribonucleoside phosphorothioate chimeras: thermal stability and antisense inhibition of gene expression. Nucl Acids Res. 1997;25:3310–3317
  44. Srinivasan SK, Iversen P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal. 1995;9:129
  45. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature. 1992;355:564
  46. Henry, S. P. Novotny, W. Leeds, J. Auletta, C. Kornbrust, D. J. Inhibition of Coagulation by a Phosphorothioate Oligonucleotide. Carlsbad, USA, Isis Pharmaceuticals, Inc. 1995
  47. Bayever E, Iversen P, Smith L, Spinolo J, Zon G. Guest editorial: systemic human antisense therapy begins. Antisense Res Dev. 1992;2:109–110
  48. Skorski T, Szczylik C, Ratajczak MZ, Malaguarnera L, Gewirtz AM, Calabretta B. Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J Exp Med. 1992;175:743–750
  49. Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Helene C, et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Nat Acad Sci USA. 1994;91:10460–10464
  50. Godard G, Boutorine AS, Saison-Behmoaras E, Helene C. Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. Eur J Biochem. 1995;232:404–410
  51. Liao Y, Tang ZY, Liu KD, Ye SIZ. Apoptosis of human BEL-7402 hepatocellular carcinoma cell released by antisense H-ras DNA-in vitro and in vivo studies. J Cancer Res Clin Oncol. 1997;123:25–33
  52. Overbeck AF, Brtva TR, Cox AD, Graham SM, Huff SY, Khorsavi-Far R, et al. Guanine nucleotide exchange factor: activators of ras super family proteins. Mol Repro Dev. 1995;42:468–476
  53. Kohl NE, Wilson FR, Mosser SD, Giuliani E, Desolms SJ, Conner MW, et al. Protein farnesylase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Nat Acad Sci USA. 1994;91:9141–9145
  54. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, Desolms SJ, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1995;1:792–797
  55. Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, et al. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene. 1995;10:1763–1779
  56. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem. 1995;270:6221–6226
  57. Prendergast GC, Davide JP, Desolms SJ, Giuliani EA, Gibbs JB, Oliff A, et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 1994;14:4193–4202
  58. Chen G, Oh S, Monia BP, Stacey DW. Antisense oligonucleotides demonstrate a dominant role of c-Ki-ras proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem. 1996;271:28259–28265
  59. Chang EH, Miller PS, Cushman C, Devadas K, Pirollo KF, Ts’o PO, et al. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry. 1991;30:8283–8286
  60. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT, Helene C. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 1991;10:1111–1118
  61. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM. Selective inhibition ofmutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem. 1992;267:9954–19962
  62. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res. 1993;53:577–580
  63. Cooper SR, Taylor JK, Miraglia LJ, Dean NM. Pharmacology of antisense oligonucleotide inhibitors of protein expression. Pharmacol Ther. 1999;82:427–435
  64. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993;53:1743–1746
  65. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Human Gene Therapy. 1993;4:451–460
  66. Altmann KH, Fabbro SM, Dean NM, Geiger T, Monia BP, Muller M, et al. Second-generation antisense oligonucleotides: structure–activity relationship and the design of improved signal-transduction inhibitors. Biochem Soc Trans. 1996;24:630–637
  67. Szczylik C, Skorski T, Ku DH, Nicolaides NC, Wen SC, Rudnicka L, et al. Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb. Exp Med. 1993;178:997–1005
  68. Szczylik C, Skorski T, Malaguarnera L, Hetman J, Chen ST, Calabretta B. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides. Folia Histochem Cytobiol. 1996;34:129–134
  69. Nieborowska-Skorska M, Skorski T, Ratajczak MZ, Szczylik C, Malaguarnera L, Calabretta B. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells. Folia Histochem Cytobiol. 1993;31:161–167
  70. Ratajczak MZ, Ratajczak J, Kuczynski W, Light B, Lusk EJ, Gewirtz AM. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide. Exp Hematol. 1993;21:1663–1667
  71. Venturelli D, Mariano MT, Szczylik C, Valtieri M, Lange B, Crist W, et al. Down-regulated c- myb expression inhibits DNA synthesis of T-leukemia cells in most patients. Cancer Res. 1990;50:7371–7375
  72. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, et al. Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci USA. 1994;91:4499–4503
  73. Walker MJ, Silliman E, Dayton MA, Lang JC. The expression of C-myb in human metastatic melanoma cell lines and specimens. Anticancer Res. 1998;18:1129–1135
  74. Skorski T, Perotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B. Antileukemia effect of c-myc N3′-P51phosphoramidate antisense oligonucleotides in vivo. Proc Nat Acad Sci USA. 1997;94:3966–3971
  75. Leonetti C, D’Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, et al. Antitumor effect of c-myc antisense phosphorothioate oligonucleotides on human melanoma cells in vitro and in mice. J Nat Cancer Inst. 1996;88:419–429
  76. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leucemic blast crisis in SCID mice. Blood. 1996;88:1005–1012
  77. Zhao Q, Song X, Waldschmidt T, Fisher E, Krieg AM. Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood. 1996;88:1788–1795
  78. Citro G, Szczylik C, Ginobbi P, Zupi G, Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer. 1994;69:463–467
  79. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824–830
  80. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991;253:562–565
  81. Skorski T, Szczylik C, Malaguarnera L, Calabretta B. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem Cytobiol. 1991;29:85–89
  82. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, et al. Suppression of Philadelphia 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA. 1994;91:4504–4508
  83. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, et al. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst. 1997;89:124–133
  84. De Fabritis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, et al. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia. 1995;9:662–664
  85. De Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood. 1998;91:3156–3162
  86. Bellucci R, Sala R, De Propris MS, Cordone I, de Fabritiis P. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma. Leuk Lymphoma. 1999;35:471–481
  87. Bhatia R, Verfaillie CM. Inhibition of BCR-ABL expres- sion with antisense oligodeoxynucleotides restores beta 1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood. 1998;91:3414–3422
  88. Rowley PT, Keng PC, Kosciolek BA. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. Leuk Res. 1996;20:473–480
  89. Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia. 1995;9:118–130
  90. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, et al. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood. 1995;86:3891–3896
  91. O’Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, et al. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia. 1994;8:2156–2162
  92. Maran A, Waller CF, Paranjape JM, Li G, Xiao W, Zhang K, et al. 2′,5′-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood. 1998;92:4336–4343
  93. Beer-Romero P, Glass S, Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene. 1997;14:595–602
  94. Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, Penalver M, et al. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol. 1997;64:18–25
  95. Lappalainen K, Pirila L, Jaaskelainen I, Syrjanen K, Syrjanen S. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Anticancer Res. 1996;16:2485–2492
  96. Maeda N, Hoshino H, Kushida S. Inhibition of syncytium formation by antisense oligonucleotide phosphorothioates complementary to tax mRNA of human T-cell leukemia virus type 1 (HLTV-1). Leukemia. 1997;11 (Suppl 3):42–44
  97. Maeda N, Kawamura T, Hoshino H. Inhibition of human T-cell leukemia virus type 1 replication by antisense env oligodeoxynucleotide. Biochem Biophys Res Commun. 1998;243:109–112
  98. Bradbury DA, Aldington S, Zhu YM, Russell NH. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol. 1996;94:671–675
  99. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst. 1997;89:1027–1036
  100. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137–1141
  101. Tormo M, Tari AM, McDonnell TJ, Cabanillas F, Garcia-Conde J, Lopez-Berestein G. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk Lymphoma. 1998;30:367–379
  102. Campbell MJ, Dawson M, Koeffler HP. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer. 1998;77:739–744
  103. Kondo S, Shinomura Y, Kanayama S, Higashimoto Y, Kiyohara T, Zushi S, et al. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells. Oncogene. 1998;17:2585–2591
  104. Niemeyer CC, Persico MG, Adamson ED. Cripto: roles in mammary cell growth, survival, differentiation and transformation. Cell Death Differ. 1998;5:440–449
  105. Normanno N, Tortora G, De Luca A, Pomatico G, Casamassimi A, Agrawal S, et al. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep. 1999;6:1105–1109
  106. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP, et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 1997;90:1982–1992
  107. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA. 1998;95:195–200
  108. Bishop MR, Jackson JD, Tarantolo SR, O’Kane-Murphy B, Iversen PL, Bayever E, et al. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother. 1997;6:441–446
  109. Ishii H, Igarashi T, Saito T, Nakano T, Mori M, Ohyama H, et al. Retinoblastoma protein expressed in human non-Hodgkin’s lymphoma cells generates resistance against radiation-induced apoptosis. Am J Hematol. 1997;55:46–48
  110. Citro G, D’Agnano I, Leonetti C, Perini R, Bucci B, Zon G, et al. C-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res. 1998;58:283–289
  111. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer. 1994;74:2546–2554
  112. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2–5A antisense directed against telomerase RNA. Oncogene. 1998;16:3323–3330
  113. Srivastava RK, Srivastava AR, Park YG, Agrawal S, Cho Chung YS. Antisense depletion of RIalpha subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. Breast Cancer Res Treat. 1998;49:97–107
  114. Roh H, Hirose CB, Boswell CB, Pippin JA, Drebin JA. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery. 1999;126:413–421
  115. Volm M. Multidrug resistance and its reversal. Anticancer Res. 1998;18:2905–2917
  116. Bello-Reuss E, Ernest S. Expression and function of P-glycoprotein in human mesangial cells. Am J Physiol. 1994;267:C1351–C1358
  117. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Nat Acad Sci. 1987;84:265–269
  118. Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Eng J Med. 1991;325:1608–1614
  119. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. New Eng J Med. 1995;333:1380–1385
  120. Shen D-W, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, et al. Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science. 1986;232:643–645
  121. Corrias MV, Tonini GP. An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 1992;12:1431–1438
  122. Quattrone A, Papucci L, Morganti M, Coronnello M, Mini E, Mazzei T, et al. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol Res. 1994;6:311–320
  123. Nakashima E, Matsushita R, Negishi H, Nomura M, Harada S, Yamamoto H, et al. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide. J Pharm Sci. 1995;84:1205–1209
  124. Liu C, Qureshi IA, Ding X, Shan Y, Huang Y, Xie Y, et al. Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides. Clin Sci (Colch). 1996;91:93–98
  125. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 1996;56:4332–4337
  126. Sola JE, Colombani PM. Modulation of multidrug resistance with antisense oligodeoxynucleotide to mdr1 mRNA. Ann Surg Oncol. 1996;3:80–85
  127. Motomura S, Motoji T, Takanashi M, Wang YH, Shiozaki H, Sugawara I, et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdrl) antisense oligonucleotides. Blood. 1998;91:3163–3171
  128. Li X, Smyth AP, Barrett DJ, Ivy SP, von Hofe E. Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction. Leukemia. 1997;11:950–957
  129. Hiratake S, Azuma E, Nishiguchi Y, Nagai M, Ido M, Komada Y, et al. Treatment of multidrug-resistant murine leukemia with antisense mdrl oligodeoxynucleotides. Biomed Pharmacother. 1997;51:276–283
  130. Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, Juliano RL. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther. 1998;286:419–428
  131. Alahari SK, Dean NM, Fisher MH, Delong R, Manoharan M, Tivel KL, et al. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1996;50:808–819

PII: S0305-7372(00)90173-7

doi: 10.1053/ctrv.2000.0173

Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 333-350 , October 2000

Article Tools